Mineralys Q1 net loss $12.6M from $7.6M YoY; cash $301.8M; Lorundrostat pivotal trial dosed

Mineralys Therapeutics, Inc.

2023-Q1 EPS reported -$0.51

Net loss $12.6M vs $7.6M in Q1 2022; R&D expense $12.3M (up from $6.8M) driven by $4.0M milestone payment to Mitsubishi Tanabe.
Cash, equivalents & investments $301.8M as of Mar 31, 2023, up from $110.1M; expected to fund operations through mid-2025.
Initiated Advance-HTN Phase 2 pivotal trial (lorundrostat) in April 2023; topline data expected H1 2024.
Plans to initiate Launch-HTN Phase 3 (H2 2023) and a CKD Phase 2 trial (mid-2023); Launch-HTN data expected mid-2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mineralys Therapeutics, Inc. reported first quarter 2023 results: net income $12.6 million.

Period: first quarter 2023
Net income: $12.6 million
Result: reported results

Exact text from the filing

Net loss was $12.6 million for the quarter ended March 31, 2023

View on SEC.gov

Browse all earnings releases →

Mineralys Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001933414-23-000035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.